A Phase II Study of Ado-Trastuzumab Emtansine Compared to the Usual Treatment for Advanced HER2-Positive Salivary Gland Cancer

Full Title

A Phase II Trial of HER2-Targeted Therapies for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

Purpose

In this study, researchers are comparing ado-trastuzumab emtansine with the usual treatment (docetaxel and trastuzumab) in people with recurrent, inoperable, or metastatic salivary gland cancer that makes the HER2 protein. Ado-trastuzumab emtansine is a monoclonal antibody (trastuzumab) linked to a chemotherapy drug (emtansine). Trastuzumab attaches to HER2 on cancer cells and delivers emtansine to kill them.

Participants in this study will be randomly assigned to receive either ado-trastuzumab emtansine or the usual treatment (docetaxel and trastuzumab). All of the medications used in this study are given intravenously (by vein).

Contact

For more information about this study and to see if you can join, please call Dr. Alan Ho’s office at 646-608-3774.